Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone


Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Kenneth C Anderson, MD (3/29/13)

Ludwig H et al. Treatment with bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma shows significant activity and is well tolerated. Proc ASH 2012;Abstract 943.

Dr Anderson is Kraft Family Professor of Medicine at Harvard Medical School, Director of the Jerome Lipper Multiple Myeloma Center and Director of the LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, Massachusetts.